Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

U.S. Bacterial Conjunctivitis Drugs Market Declines owing to Rising Demand for Generic Antibacterial Drugs

Article Description

The demand for generic antibacterial eye drops is expected to rise in the coming few years. Thus, key companies manufacturing bacterial conjunctivitis drugs are expected to experience a downfall in the demand for their branded drugs. Patent expiry is a major challenge faced by key companies operating in this market. Generic antibacterial drugs are available in the U.S. medicine market at cheaper rates than branded drugs. This has affected the sales of branded drugs for bacterial conjunctivitis. 

The U.S. bacterial conjunctivitis drugs market is expected to exhibit a decline during the forecast period. The market stood at US$473.3 mn in 2013 and is expected to fall to US$439.8 mn by 2024. Going forward, top manufacturers such as Zymaxid Moxeza, Vigamox, and AzaSite are expected to lose their client base, which will have a significant impact on the market in the U.S.

Occurrence of Multi-drug Resistant Organisms (MDROs) to Challenge Market 

The increasing occurrence of MDROs, caused by the growing use of antibiotics, has created many challenges for treating bacterial conjunctivitis and other microbial infections. Researchers from across the globe are concentrating on introducing drugs for MDROs. The shortage of effective medication is expected to affect the growth of the U.S. bacterial conjunctivitis drugs market in the near future.

The implementation of product development partnerships (PDPs) by market players is predicted to help them overcome these challenges. As research and development activities for new drug discoveries have become expensive, strategic partnerships with startups will be beneficial for the key companies.

Changing Patient Preference to Motivate Manufacturers to Introduce New Drugs

The preference of patients is shifting from pharmacological drugs to herbal treatments. Key companies are thus focusing on introducing more herbal treatments and medicines to match the changing trends. With this, they aim to maintain their dominance in the U.S. bacterial conjunctivitis drugs market. 

As doctors in the United States report a rise in the number of people suffering from bacterial conjunctivitis, they also aim to introduce advanced eye drops and medication for treating the disease. Many people go for over-the-counter medication or self-help medication to treat their bacterial conjunctivitis. At times, over-the-counter medicines and self-medication can cause certain problems owing to the intake of improper medicines. The rising awareness among people about taking prescribed drugs and branded eye drops is expected to provide a respite for branded drugs in the coming years.

Actavis plc., Bayer AG, Merck & Co., Inc., Perrigo Company plc., Santen Pharmaceutical Co., Ltd., Akorn, Inc., F. Hoffmann-La Roche, Ltd., Novartis AG, Pfizer, Inc., and Valeant Pharmaceuticals International, Inc. are some of the companies manufacturing eye drops for treating bacterial conjunctivitis.

Browse Full U.S. Bacterial Conjunctivitis Drugs Market Report with TOC:http://www.mrrse.com/us-bacterial-conjunctivitis-drugs-industry

By drug class, the U.S. bacterial conjunctivitis drugs market is classified into fluoroquinolones, aminoglycosides, macrolides, and others. The fluoroquinolones drug class is sub-divided into ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, and besifloxacin.